🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

TELA Bio divests NIVIS rights to MiMedx for up to $12 million

EditorEmilio Ghigini
Published 03/20/2024, 07:24 AM
© Reuters.

MALVERN, Pa. - TELA Bio, Inc. (NASDAQ:TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the sale of its NIVIS Fibrillar Collagen Pack distribution rights to MiMedx Group, Inc., an Atlanta-based company known for its regenerative biomaterial products and therapies.

The deal, which could reach a total consideration of up to $12 million, includes an upfront payment of $5 million from MiMedx, with additional future payments ranging from $3 million to $7 million, contingent on NIVIS's net sales over the forthcoming two-year period.

NIVIS, an absorbent collagen matrix, is used for managing wounds with moderate to heavy exudation and for controlling minor bleeding. The acquisition by MiMedx, a company that focuses on healing solutions in wound care, burn, and surgical healthcare sectors, aims to enhance the market presence of this TELA Bio-designed product.

Antony Koblish, President and CEO of TELA Bio, expressed confidence in MiMedx's ability to increase the market share and deliver NIVIS to a broader audience of surgeons and patients. He also stated that TELA Bio looks forward to expanding its own portfolio, which includes new hernia repair and reconstructive surgery products, such as the LIQUIFIX hernia mesh fixation devices and OviTex Reinforced Tissue Matrices.

TELA Bio has positioned itself as a provider of advanced soft-tissue reconstruction solutions that prioritize patient anatomy preservation and natural healing, while minimizing exposure to permanent synthetic materials.

This transaction is part of TELA's strategic efforts to focus on its core product lines and enhance its financial position. The company has not provided guidance on the expected financial impact of the sale.

The information for this report is based solely on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.